Whalesbook
Toh bhai log, PI Industries (PIIND) ne Q3 FY26 ke results reveal kiye hain aur picture kaafi mix hai. Pehle baat karte hain standalone performance ki. Yahan revenue 28.6% YoY kam hokar ₹12,696 million ho gaya ₹17,798 million se. Profit After Tax (PAT) toh 33.5% YoY tut gaya, ₹4,238 million se seedha ₹2,816 million pe aa gaya. Matlab, standalone level pe company ko kaafi pressure face karna pad raha hai. Basic aur diluted EPS bhi ₹27.93 se ₹18.56 pe aa gaye. EBITDA bhi 33.3% YoY gir kar ₹3,655 million raha, aur margins bhi thode down hue 30.79% se 28.79%. Ek chota sa exceptional loss bhi tha ₹206 million ka.
Ab jab consolidated numbers dekhte hain, toh yahan bhi revenue 27.6% YoY gira, ₹19,008 million se ₹13,757 million. Lekin consolidated PAT mein 16.5% YoY ka spike dikha, ₹3,727 million se ₹3,113 million. Ab yeh bada jump ₹1,051 million ke exceptional gain ki wajah se aaya hai, jismein pehle ke acquisitions se related write-back aur labour code changes ka impact hai. Agar is gain ko hata dein, toh operating profit (EBITDA) toh 46.4% YoY gir gaya tha! Aur consolidated margins bhi 25.29% se 18.74% pe aa gaye. Consolidated EPS bhi 16.5% YoY gir gaya.
Segments ki baat karein toh Agro Chemicals business ki revenue 28.4% YoY kam hui, aur PBT 46.4% gir gaya. Pharma segment mein bhi revenue 6.3% YoY gira, jo ₹599 million raha. Lekin Pharma ka PBT accha tha ₹580 million ka.
Toh asli picture kya hai? Yeh results clearly dikha rahe hain ki business mein demand aur execution ko lekar pressure hai, especially standalone side pe. Consolidated PAT ka badhna sirf one-off gains ki wajah se hai, jo asli operational performance ko mask kar raha hai. Jab operating profit itna gir raha hai aur margins compress ho rahe hain, toh yeh cheezenechintajanak hain. Consolidated EPS ka girna bhi dikhata hai ki per share value pe impact pada hai. Investors ab yeh dekhna chahenge ki bina is exceptional gain ke company future mein kaise perform karti hai. Agro Chemicals mein jo slowdown aur margins ka pressure hai, woh ek bada risk hai. Pharma segment mein bhi recovery dekhni hogi. Company ne ₹5 per share ka interim dividend declare kiya hai, record date February 23, 2026 hai. Ab dekhna hoga ki management aage kya strategy le kar aati hai.